Paladin Partners’s Avanos Medical AVNS Stock Holding History

Paladin Partners’s Portfolio AVNS Stock Details AVNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$597	Hold	24	–	–	﹤0.01%	202
2026 Q1	$336	Hold	24	–	–	﹤0.01%	204
2025 Q4	$270	Buy	+24	New	+$275	﹤0.01%	210

Other funds holding AVNS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NAM

Nexpoint Asset Management Dallas, Texas $1.5B AUM 83.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TAL

TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

FTCM

First Trust Capital Management Chicago, Illinois $1.72B AUM 70.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Paladin Partners's AVNS Position: Q2 2026 in Review

Paladin Partners held its Avanos Medical (AVNS) position steady in Q2 2026 at 24 shares worth $597. The position accounts for ﹤0.01% of the portfolio, ranked #202.

Paladin Partners first reported a position in AVNS in Q4 2025 and has held it in 3 quarters since. 286 funds tracked by Wall St. Rank hold AVNS as of Q2 2026.

Paladin Partners held 24 shares of Avanos Medical worth $597 as of Q2 2026.
Paladin Partners left its Avanos Medical share count unchanged in Q2 2026.
Avanos Medical made up ﹤0.01% of Paladin Partners's portfolio in Q2 2026, its #202 holding.
Paladin Partners first reported a position in Avanos Medical in Q4 2025 and has held it in 3 quarters since.
286 funds tracked by Wall St. Rank held Avanos Medical as of Q2 2026.

Based on Paladin Partners's 13F filing for Q2 2026, filed 7 Aug 2026.